Clinical trial · no report yet · Phase 3
SUNRAY-01
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- NCT06119581 ↗
- Recruiting
- Eli Lilly and Company
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis
- Interventions
- LY3537982; Pembrolizumab; Placebo; Cisplatin; Carboplatin; Pemetrexed
- Arms
- Dose Optimization: LY3537982 Dose Level 1 plus Pembrolizumab · Experimental
- Dose Optimization: LY3537982 Dose Level 2 plus Pembrolizumab · Experimental
- Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum · Experimental
- Part A: LY3537982 plus Pembrolizumab · Experimental
- Part A: Placebo plus Pembrolizumab · Placebo comparator
- Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum · Experimental
- Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum · Placebo comparator
- Part C: LY3537982 plus Pembrolizumab · Experimental
- Enrollment
- 1,264 (estimated)
- Primary outcomes
- Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)
- Part A and Part B: Progression-Free Survival (PFS)
- Sponsor
- Eli Lilly and Company
- Start
- Dec 21, 2023
- Primary completion
- Nov 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06119581 · updated Oct 7, 2026
Publications
linked from the registry- Peters S, Hochmair M, Arbour KC, Rodriguez LP, Reck M, Leal T, R Lindsay C, Shun L, William WN, Spira AI, Sabari JK, Henning Gronberg B, Nishio M, Burns TF, Girard N, Capuzzo F, Merced A, Fasnacht N, Visseren-Grul C, Negrao MV. SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. Future Oncol. 2026 Apr;22(9):1073-1082. doi: 10.1080/14796694.2026.2651961. Epub 2026 Apr 6. PubMed 41940628